Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to CMS about Proposed Decision for Medicare Coverage of NGS for Advanced Cancer
-
ACMG Comments to CMS Regarding CY 2020 CLFS Preliminary Payment Determinations
-
ACMG Comments to CMS Regarding NCD 90.2 and Medicare Coverage of NGS for Advanced Cancer
-
Group Sign-on Letter to CMS Requesting Extension of Comment Period Regarding NGS Coverage Reconsideration
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
Group Sign-on Letter to CMS Supporting CY 2019 PFS Changes to Reduce E/M Documentation Burden
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)